What the label states, the lot delivers — net peptide mass, not gross powder weight, purity reported as measured rather than rounded up, and a Certificate of Analysis for every lot.
Net peptide mass, not powder weight; purity as measured, not rounded up; a COA per lot.
Net peptide + purity not rounded up. COA per lot.
FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
Prohibitin-targeting adipose vascular peptide
Overview
Adipotide (Prohibitin-TP01/TP01, also called FTPP or HKPao) is a chimeric, adipose-vasculature-targeted peptidomimetic developed at the University of Texas MD Anderson Cancer Center / UTHealth Houston (Kolonin, Pasqualini, and Arap laboratories), later licensed to Arrowhead Research (now Arrowhead Pharmaceuticals) for clinical development. Its CKGGRAKDC targeting domain recognizes the prohibitin/annexin A2 (ANXA2) receptor pair expressed on white adipose tissue vascular endothelial cells, and delivers a pro-apoptotic D-(KLAKLAK)2 payload that causes the supporting blood vessels to undergo apoptosis, in turn depriving adipocytes of blood supply and triggering their apoptosis. Rapid fat loss and improved insulin resistance were observed in obese animal models (mice and rhesus monkeys). Around 2011, MD Anderson initiated a human Phase 1 trial (NCT01262664) in patients with castration-resistant prostate cancer and obesity; the trial registry marks it as "Terminated," with the officially listed reason being "Terminated per PI's request" (Principal Investigator Dr. Amado Zurita; the trial ran from May 2012 to January 2019 and enrolled only 4 of a planned 39 patients). The compound is currently used only as a research reference material, is not an approved human drug, and has no FDA-approved indication. Vialdyne releases Adipotide (FTPP) as a lyophilized bicyclic homing-domain / pro-apoptotic peptide conjugate (disulfide-cyclized ckggrakdc nonapeptide + gg linker + d-amino-acid d(klaklak)2 tandem-repeat domain) against a ≥ 99.0% HPLC main-peak specification, with a batch-specific Certificate of Analysis covering RP-HPLC purity, mass-spec identity, water content, residual solvents, and endotoxin. Sequence / identity confirmation is documented on the released lot.
Applications & buyer fit
Most buyers in this category are 503A and 503B compounding pharmacies fulfilling metabolic and weight-management protocols, plus research labs investigating GLP-1 / GIP / GCG receptor pharmacology. The procurement decision usually hinges on three things: documented purity at scale, a regulatory team that can respond on destination-market questions in writing, and the ability to supply consistent counter-ion form (acetate by default) across recurring orders.
Sourced for
Buyer fit
Documentation that ships
Procurement note: Supplied as a documented active in acetate counter-ion form by default; the buyer verifies current scheduling and compounding eligibility for the destination market.
Primary buyer fit: academic and contract research laboratories.
Specifications
Regulatory note
Research-use-only reference material; not for human or veterinary use.
Selected literature
Frequently asked questions
Adipotide's activity depends on two features that plain mass measurement cannot resolve: the N-terminal homing motif must be disulfide-cyclized rather than left as the linear precursor, and the effector segment must be built from D-amino acids. Total mass will not separate a cyclized from a non-cyclized species reliably, nor D- from L-residues. Accept a lot against sequence-level confirmation spanning both the homing and effector domains, with RP-HPLC purity distinguishing the intended cyclic product from linear or misfolded forms. Confirm net-peptide content too, so counter-ion and moisture are excluded from the mass you dose in target-vasculature work.
Keep the lyophilized material sealed, desiccated, and frozen, and aliquot after reconstitution to limit freeze-thaw exposure that can drive aggregation or promote disulfide scrambling in the cyclic homing motif. Reconstitute in a vehicle matched to the compound's documented solubility, and avoid conditions that would reduce or reshuffle the disulfide, since loss of the correct ring would compromise the vascular-homing function while leaving the mass largely unchanged. Prepare working solutions close to use, hold them cold, and record preparation dates so any change in behavior can be attributed to solution handling rather than to the received lot.
